Clinical Study of Erzhi Pill and Guizhi Decoction on the Treatment of Triple Negative Breast Cancer

b>OBJECTIVE To study the clinical efficacy of Erzhi pill and Guizhi decoction in the treatment of triple negative breast cancer(TNBC). METHODS The data of 100 TNBC cases diagnosed in breast department from January 2013 to January 2015 were retrospectively analyzed. The case data of routine adjuvant chemotherapy after operation were the control group(50 cases), and the case data of the treatment group(50 cases) treated with Erzhi pill and Guizhi decoction. Five-year follow-up was conducted to compare and analyze the differences in efficacy, physical function, quality of life and tumor markers between the two groups. Adverse events during treatment were recorded, and differences in 5-year overall survival, disease-free survival, and recurrence and metastasis rates were compared. RESULTS The total effective rate of 80.00% in the treatment group was higher than that of 62.00% in the control group(P<0.05). After treatment, the stabilization rate of KPS score improvement in the treatment group was 82.00% which was higher than that in the control group of 70.00%(P<0.05), and the FACT-B score was higher(P<0.05). The levels of serum tumor markers CEA, CA125 and CA153 in the treatment group were decreased and lower than control troup(P<0.05). The gastrointestinal adverse reactions in the treatment group were milder than control troup(P<0.05). The 5-year overall survival rate and disease-free survival rate of 88.00% and 62.00% in the treatment group which was were higher than those of 72.00% and 42.00% in the control group (P<0.05). CONCLUSION Erzhi pill and Guizhi decoction have significant effect on TNBC patients, which can improve the life quality of patients, and have good long-term effect, which is worthy of clinical application.